Results 11 to 20 of about 58,504 (176)

Irinotecan-Induced Dysarthria [PDF]

Case Reports in Oncology, 2012
Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second ...
IJke J. Aalders, Johannes C. van der Mijn, Rico N.P.M. Rinkel, Hans J. van der Vliet, Albertine J. Dressel   +4 more
core   +5 more sources

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity [PDF]

BMC Microbiology, 2023
Background Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion ...
Marwa S. Mahdy, Ahmed F. Azmy, Tarek Dishisha, Wafaa R. Mohamed, Kawkab A. Ahmed, Ahmed Hassan, Sahar El Aidy, Ahmed O. El-Gendy   +7 more
doaj   +2 more sources

Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.

PLoS ONE, 2015
Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment.
Seung Ho Choi, Hye Kyung Hong, Yong Beom Cho, Woo Yong Lee, Hae Yong Yoo   +4 more
doaj   +2 more sources

Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report [PDF]

Case Reports in Oncology, 2021
Irinotecan hydrochloride (irinotecan) is a chemotherapeutic agent used in the treatment of solid tumors. In addition to severe neutropenia and delayed diarrhea, irinotecan causes cholinergic syndrome, characterized by abdominal pain and acute diarrhea ...
Kazuki Uchiyama, Yoshitaka Saito, Yoh Takekuma, Satoshi Yuki, Mitsuru Sugawara   +4 more
doaj   +2 more sources

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer

BMC Gastroenterology, 2018
Background For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis ...
Liuting Yang, Xiaoyue Jiang, Han Yan, Yingying Li, Hongchao Zhen, Bingmei Chang, Seyed Kariminia, Qin Li   +7 more
doaj   +2 more sources

Contribution of HIF-1α/BNIP3-mediated autophagy to lipid accumulation during irinotecan-induced liver injury

Scientific Reports, 2023
Irinotecan is a topoisomerase I inhibitor which has been widely used to combat several solid tumors, whereas irinotecan therapy can induce liver injury.
Congjian Shi, Zhenghong Zhang, Renfeng Xu, Yan Zhang, Zhengchao Wang   +4 more
doaj   +2 more sources

Protective role of Lactobacillus plantarum A7 against irinotecan-induced genotoxicity [PDF]

Avicenna Journal of Phytomedicine, 2016
Objective: Irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. The present study evaluated the effect of Lactobacillus plantarum A7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell ...
Soheila Sepahi, Abbas Jafarian-Dehkordi, Maryam Mirlohi, kobra shirani, Mahmoud Etebari   +4 more
doaj   +1 more source

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma

Cancer Medicine, 2023
Background Subgroup analyses of the NAPOLI‐1 study identified that among patients who were irinotecan naïve prior to entering the clinical trial, a survival benefit was observed between the study arm and control arm.
Kenneth H. Yu, Paul Cockrum, Andy Surinach, Neil Lamarre, Shu Wang, Eileen M. O'Reilly   +5 more
doaj   +2 more sources

Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis

Cancer Cell International
Background Irinotecan is a widely used chemotherapy drug in colorectal cancer (CRC). The evolution and prognosis of CRC involve complex mechanisms and depend on the drug administered, especially for irinotecan.
Chengyi Huang, Bufu Tang, Wenjuan Chen, Jinggang Chen, Huojun Zhang, Minghua Bai   +5 more
doaj   +2 more sources

The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice

Pharmaceuticals, 2020
Irinotecan, an anticancer drug, induces diarrhea and intestinal inflammation, resulting in an increase in the cost of care and in treatment delays.
Daniely V. S. Costa, Deiziane V. S. Costa, Caren N. S. Sousa, Angeline M. H. P. Silva, Ingridy S. Medeiros, Dainesy S. Martins, Conceição S. Martins, Ana L. V. Pequeno, Roberto C. P. Lima-Júnior, Pedro M. G. Soares, Silvânia M. M. Vasconcelos, Gerly A. C. Brito, Emmanuel P. Souza   +12 more
doaj   +2 more sources